UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~October~~November 15, 2025

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-39509	~~001~~36-~~39509~~4883909	~~36-4883909~~
(State or Other Jurisdictionof Incorporation)	(CommissionFile Number)	(~~CommissionFile~~IRS ~~Number~~EmployerIdentification No.)	~~(IRS EmployerIdentification No.)~~
1560 Trapelo RoadWaltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

1560 Trapelo RoadWaltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value per share	DYN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 Results ~~Departure~~ of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

On ~~October~~November 15, 2025, ~~the Board of Directors (the “Board”) of~~ Dyne Therapeutics, Inc. (the “Company”), ~~upon~~issued ~~recommendation from the Nominating and Corporate Governance Committee of the Board, elected Brian Posner as~~ a ~~Class~~press ~~III~~release ~~director~~announcing ~~to serve on~~ the ~~Board until the~~ Company’s ~~2026~~financial ~~Annual~~results ~~Meeting~~for ofthe ~~Stockholders~~quarter ~~and~~ended ~~until~~September ~~his successor has been duly elected and qualified or until his earlier death~~30, ~~resignation or removal~~2025. ~~Mr.~~A ~~Posner~~copy ~~has not been appointed to serve on any committees~~ of the ~~Board.~~press ~~The~~release ~~Board~~is ~~has~~furnished ~~determined~~as ~~that~~Exhibit Mr99.1 ~~Posner~~to isthis anCurrent ~~“independent”~~Report ~~director~~on ~~under~~Form ~~the~~8-K ~~Nasdaq~~and ~~Stock~~is ~~Market~~incorporated ~~rules.~~herein by reference.

~~Mr.~~The ~~Posner~~information ~~shall~~in bethis ~~entitled~~Form ~~to receive compensation under the Company’s non~~8-~~employee director compensation program. In accordance with this program~~K, ~~upon~~including ~~his~~Exhibit ~~election to the Board, Mr~~99.1 ~~Posner~~attached ~~received~~hereto, ~~under~~is ~~the~~being ~~Company’s~~furnished ~~2020~~and ~~Stock~~shall ~~Incentive~~not ~~Plan,~~be andeemed ~~option~~“filed” tofor ~~purchase~~purposes ~~70,000 shares~~ of ~~the~~Section ~~Company’s~~18 ~~common stock at an exercise price equal to $12.50 per share, the closing price~~ of the ~~Company’s~~Securities ~~common~~Exchange ~~stock~~Act ~~on the date~~ of ~~grant~~1934, ~~which~~as ~~option~~amended ~~will vest and become exercisable in equal monthly installments over~~ (the ~~next~~“Exchange ~~three years~~Act”), or otherwise subject to ~~his continued service. In~~ the ~~event~~liabilities of athat ~~change in control of the Company~~section, ~~the~~nor ~~vesting~~shall ~~schedule~~it ofbe ~~the~~deemed ~~option~~incorporated ~~will~~by ~~accelerate~~reference ininto ~~full.~~any Infiling ~~addition,~~by ~~Mr.~~the ~~Posner~~Company ~~will~~under ~~receive~~the ~~annual~~Securities ~~cash~~Act ~~compensation~~ of ~~$45~~1933,~~000~~ as ~~a member of the Board~~amended, ~~annual~~or ~~equity grants in accordance with~~ the ~~non-employee~~Exchange ~~director~~Act, ~~compensation~~except ~~program~~as ~~and~~expressly ~~reimbursement~~set ~~for~~forth ~~reasonable~~by ~~travel~~specific ~~and~~reference ~~out-of-pocket expenses incurred~~ in ~~connection~~such ~~with attending Board meetings~~filling.

~~There~~Item ~~are no arrangements or understandings between Mr~~9.01 Financial ~~Posner~~Statements and ~~any other persons pursuant to which he was elected as a director~~Exhibits. Mr. Posner does not have any family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Mr. Posner and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

~~Mr.~~(d) ~~Posner~~Exhibits will enter into the Company’s standard form of indemnification agreement. The form of the indemnification agreement was filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission on August 25, 2020.


Exhibit No.		Description

99.1 104		Press Release issued by Dyne Therapeutics, Inc. on November 5, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DYNE THERAPEUTICS, INC.	~~DYNE THERAPEUTICS, INC.~~
Date: October 2, 2025		By:	/s/ John G. Cox
Date: November 5, 2025	By:	/s/ John G. Cox
		Name:	John G. Cox
		Title:	President and Chief Executive Officer

Filing Compare · Dyne Therapeutics, Inc.